AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CORCEPT THERAPEUTICS INC Director's Dealing 2021

Jan 27, 2021

30681_dirs_2021-01-26_05ea1f56-e38f-4eeb-9f25-8b9724398946.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CORCEPT THERAPEUTICS INC (CORT)
CIK: 0001088856
Period of Report: 2021-01-22

Reporting Person: BELANOFF JOSEPH K (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	M	800000	$4.42	Acquired	3299214	Direct
2021-01-22	Common Stock	F	481088	$28.06	Disposed	2818126	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-22	Stock Option (Right to Buy)	$4.42	M	800000	Disposed	2021-05-19	Common Stock (800000)	Direct

Footnotes

F1: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on January 22, 2021. The options subject to the net exercise were to expire on May 19, 2021.

F2: Fully exercisable.